Ning Wu

Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC

Shugeng Gao, Ning Li, Shun‐Yu Gao et al. · Journal of Thoracic Oncology · 2020 · 415 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advancedEGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study

Yuankai Shi, L. Wang, Baohui Han et al. · Annals of Oncology · 2017 · 338 citations

Medicine, Oncology, Pharmacotherapy +10

Genomic heterogeneity of multiple synchronous lung cancer

Yu Liu, Jianjun Zhang, Li Lin et al. · Nature Communications · 2016 · 215 citations · Full text

Medicine, Genetics, Oncology +17

A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy

Jiangdian Song, Jingyun Shi, Di Dong et al. · Clinical Cancer Research · 2018 · 198 citations

Medicine, Oncology, Pharmacology +17

Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer: Perfusion CT Evaluation of Chemotherapy and Radiation Therapy

Jianwei Wang, Ning Wu, Matthew D. Cham et al. · American Journal of Roentgenology · 2009 · 149 citations

Medicine, Oncology, Radiology +17